The National Cancer Institute (NCI) offers the Specialized Programs of Research Excellence (SPORE) grant, a P50 Research Center opportunity. This grant supports cutting-edge, investigator-initiated translational research aimed at enhancing the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research includes cancers derived from the same organ system, those sharing a common biological mechanism like an infectious agent or signaling pathway, or cross-cutting themes such as pediatric cancers and health disparities. Projects must focus on human biology, utilizing cellular, molecular, structural, biochemical, and/or genetic experimental approaches. A core requirement is achieving a translational human endpoint within the grant’s project period, ensuring direct clinical relevance and impact.
Opportunity ID: 350299
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-284 |
| Funding Opportunity Title: | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Sep 22, 2023 |
| Last Updated Date: | Sep 22, 2023 |
| Original Closing Date for Applications: | Sep 25, 2026 |
| Current Closing Date for Applications: | Sep 25, 2026 |
| Archive Date: | Oct 31, 2026 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Special district governments County governments For profit organizations other than small businesses Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments Independent school districts Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-284.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 350299 Full Announcement-PAR-23-284 -> PAR-23-284-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00283231 | Dec 25, 2023 | Jan 24, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289313 | Dec 02, 2024 | Sep 25, 2026 | View |
Package 1
Mandatory forms
350299 RR_SF424_5_0-5.0.pdf
350299 PHS398_CoverPageSupplement_5_0-5.0.pdf
350299 RR_OtherProjectInfo_1_4-1.4.pdf
350299 PerformanceSite_4_0-4.0.pdf
350299 RR_KeyPersonExpanded_4_0-4.0.pdf
350299 PHS398_ResearchPlan_5_0-5.0.pdf
350299 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
350299 PHS_Additional_IndirectCosts_2_0-2.0.pdf
350299 PHS_AssignmentRequestForm_4_0-4.0.pdf
Package 2
Mandatory forms
350299 RR_SF424_5_0-5.0.pdf
350299 PHS398_CoverPageSupplement_5_0-5.0.pdf
350299 RR_OtherProjectInfo_1_4-1.4.pdf
350299 PerformanceSite_4_0-4.0.pdf
350299 RR_KeyPersonExpanded_4_0-4.0.pdf
350299 PHS398_ResearchPlan_5_0-5.0.pdf
350299 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
350299 PHS_Additional_IndirectCosts_2_0-2.0.pdf
350299 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
